LIDE’s Industry-Leading Patient‑Derived Xenograft (PDX) Biobank
LIDE offers one of the world’s largest and most clinically annotated PDX libraries, with over 2300 low-passage, patient-derived models covering nearly 50 cancer types, all sourced ethically and validated under rigorous scientific standards.
| Cancer Type | # of PDX |
|---|---|
| Acute Lymphocytic Leukemia (ALL) | 12 |
| Acute Myeloid Leukemia (AML) | 28 |
| Adenocarcinoma of Seminal Vesicle | 2 |
| Adenoid Cystic Carcinoma (ACC) | 6 |
| Bladder Cancer | 17 |
| Brain Cancer | 63 |
| Breast Cancer | 65 |
| Burkitt Lymphoma (BL) | 1 |
| Carcinoma of Esophagogastric Junction | 23 |
| Cervical Cancer | 72 |
| Cholangiocarcinoma | 76 |
| Chordoma | 2 |
| Chronic Lymphocytic Leukemia (CLL) | 1 |
| Chronic Myelogenous Leukemia (CML) | 1 |
| Diffuse Large B-Cell Lymphoma (DLBCL) | 15 |
| Duodenal Cancer | 14 |
| Endometrial Cancer | 21 |
| Esophageal Cancer | 28 |
| Fallopian Tube Carcinoma | 2 |
| Gallbladder Cancer | 31 |
| Gastrointestinal Stromal Tumor | 10 |
| Gastric Cancer | 217 |
| Head and Neck Cancers | 52 |
| Hepatoblastoma | 46 |
| Hodgkin’s Lymphoma (HL) | 2 |
| HL Transformed into DLBCL | 1 |
| Liver Cancer | 133 |
| Lung Cancer | 164 |
| Malignant Pleural Mesothelioma | 3 |
| Mantle Cell Lymphoma (MCL) | 2 |
| Mediastinal Endoblastoid Sinus Tumor | 1 |
| Melanoma | 11 |
| Mucinous Carcinoma | 5 |
| Multiple Myeloma (MM) | 9 |
| Neoplasm of Skin | 4 |
| Neurilemmoma | 1 |
| Neuroblastoma | 14 |
| Neuroendocrine Carcinoma (NEC) | 48 |
| Ovarian Cancer | 231 |
| Paget’s Disease | 1 |
| Pancreatic Cancer | 313 |
| Penile Cancer | 2 |
| Peripheral T Cell Lymphoma (PTCL) | 5 |
| Periampullary Carcinoma | 5 |
| Prostate Cancer | 5 |
| Rectal Cancer | 86 |
| Renal Cancer | 16 |
| Richter Transformation (RT) | 1 |
| Sarcomas | 188 |
| Spleen Cancer | 1 |
| T-cell Prolymphocytic Leukemia (T-PLL) | 1 |
| Unknown Origin Tumor | 11 |
| Urethral Cancer | 2 |
| Lymphoma – Not Classified | 8 |
Table: Summary of available PDX Models. Updated 2025JUL31
Leverage our patient derived xenograft models and partner with LIDE on your next oncology research project:
- Ex Vivo screens
- In vivo efficacy studies
- 3D in-vivo studies using MiniPDX
- Immunotherapy evaluation on huPBMC reconstituted models
- Over 370 drug resistant models
- Naturally occurring in patients and revalidated after model establishment. Find models resistant to drugs like enhertu, osimertinib, BTK inhibitors, and others.
- 200 models harboring clinically relevant alterations
- Over 200 models harboring clinically relevant alterations—EGFR, KRAS, HER2 amplification, ALK/ROS1/NTRK fusions, BRAF V600E, PTEN and PIK3 mutations—many derived from pretreated or refractory tumors.
- Full clinical annotations, well characterized
- Over 900 models with full treatment histories, ethically sourced and patient consented, bringing unparalleled understanding of your models. Most of our models include sequencing data, SOC studies and growth kinetics.
- Unmatched diversity, readily available
- Almost 50 indications covered and almost 300 models actively revived for immediate studies.
| Cancer Type | Resistant to | Specific Genetic Alteration |
|---|---|---|
| NSCLC | Erlotinib Osimertinib Czotinib Brigatinib anti PD-L1 abri | Specific Genetic Alteration EGFR: exon19del/T790M/L858R/exon20ins/ C797S ALK: EML4-ALK/L1196MCrizotinib cMET: ampli/exon14ski/CD47-MET RET: KIF5B-RET ROS1: CD74-ROS1/G2032R KRAS: G12C PTEN: Y68X PI3K: E726K |
| Breast Cancer | CDK4/6i | TNBC/ER+ |
| Multiple Myeloma | Bortezomib | CD47+/CD38+ |
| Cholangiocarcinoma | Paclitaxel | KRAS: G12C FGFR: BICC1-FGFR2 |
| Colorectal Cancer | Avastin | KRAS: G12C BRAF: V600E |
| Hematological Malignancy | Rituximab Imatinib | / / |
| Gastric Cancer | Herceptin | HER2: ampli KRAS: G12C EGFR: VIII |
| Brain Cancer | / | cMET: PTPRZ1-MET |
| Melanoma | anti PD-1 ab | BRAF: V600E |
| Ovarian Cancer | Platinum PARPi | / |
| Research Phase | Leveraging LIDE’s PDX Library |
| Target ID & Hit Discovery | Use our rapid ex-vivo assays for high-diversity cohort screens to identify responsive subtypes and targets |
| Lead Optimization & Preclinical Validation | Confirm on-target activity and drug sensitivity prior to optimization and lead selection |
| Indication Screening | Evaluate lead compounds across diverse indications to inform go/no-go decisions |
| Biomarker Discovery & CDx Development | Link genotype or phenotype to drug response using integrated omics and functional data |
Model Validation and Quality Assurance
Our PDX biobank was built from the beginning according to standards set by a consortium led by LIDE in collaboration with EMD Serono, Eli Lilly and Merck. Our models adhere to strict quality control aligned with the industry best practices:
- Genomic profiling with Whole-Exome Sequencing and RNA-Seq. Search genomic data in our online database.
- Low-passaged to minimize mouse-adaptive drift while preserving tumor heterogeneity. Most studies done at P3-P5.
- Morphology validation with H&E. Target expression analysis with IHC.